1056: THE EFFICACY OF THE POLIMYXIN B IMMOBILIZED FIBER COLUMN DIRECT HEMOPERFUSION FOR SEPTIC SHOCK

    loading  Checking for direct PDF access through Ovid

Excerpt

Learning Objectives: Many patients with septic shock receive Polimyxin B immobilized fiber column direct hemoperfusion (PMX-DHP) as a rescue therapy. A purpose of this study is to clarify an effect of PMX-DHP for the prognosis of patients with septic shock. The aim of the study was to determine the effects of PMX-DHP on the prognosis of the patients with septic shock in a case-control setting.
Methods: Data from patients admitted for severe sepsis or septic shock to Japanese ICUs were retrospectively collected from Jan 2011 to Dec 2013 through the J-SEPTIC DIC (Japanese society of education for physicians and trainees in intensive care disseminated intravascular coagulation) study data base set. We analyzed the potential benefit of PMX-DHP using a propensity score–matched (1:1) cohort analysis in septic shock patients.
Results: Of 1754 eligible patients, 522 underwent PMX-DHP. Propensity score matching created a matched cohort of 640 patients (320 pairs with and without PMX-DHP). There was no significant difference between the two matched cohorts for the ICU mortality (PMX-DHP; 24.4% vs non-PMX-DHP; 25.9%, p=0.650). On the other hand PMX-DHP treatment was significant improvement of the hospital mortality compared with non-PMX-DHP treatment (PMX-DHP; 33.1% vs non-PMX-DHP; 43.4%, p=0.01).
Conclusions: In this demonstrated that PMX-DHP had a benefit on hospital survival when compared with conventional management (non-PMX-DHP) in matched patients of similar severity. A large multicenter prospective randomized trial is going now to confirm the efficacy of PMX-DHP treatment in septic shock.

Related Topics

    loading  Loading Related Articles